BlackRock Fund Advisors recently announced the acquisition of new stake in Repligen Corp. (NASDAQ:RGEN). The institutional investor has increased its shareholding in the Healthcare company by 0.00% to 4.96 million shares with purchase of 97.0 shares. This fresh investment now brings its stake to 8.88% valued currently at $890.91 million. In addition, T. Rowe Price Associates, Inc. raised its holdings by 81971.0 to 3.76 million shares. And BlackRock Advisors LLC has lifted its position by 14.31% or 0.23 million shares – to 1.81 million shares.
With over 0.44 million Repligen Corp. (RGEN) shares trading Friday and a closing price of $173.21 on the day, the dollar volume was approximately $76.64 million. The shares have shown a positive half year performance of 15.10% and its price on 01/12/24 lost nearly -3.02%. Currently, there are 55.56M common shares owned by the public and among those 51.91M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 13 analysts who have offered their price forecasts for RGEN have a consensus price objective of $184.92. The analysts have set the share’s price value over the next 12 months at a high of $211.00 and a low of $148.00. The average price target is 6.33% above its recent price level and a downside to the estimated low will see the stock lose -17.03% over that period. But an upside of 17.91% will see the stock hit the forecast high price target while median target price for the stock is $185.00.
Insiders at the company have transacted a total of 44 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 23 of these insider trades were purchases, accounting for 81,780 shares. Insider sales of the common stock occurred on 21 occasions, with total insider shares sold totaling 28,346 shares.
The top 3 mutual fund holders in Repligen Corp. are T Rowe Price New Horizons Fund, Vanguard Total Stock Market ETF, and iShares Core S&P Mid Cap ETF. T Rowe Price New Horizons Fund owns 2.46 million shares of the company’s stock, all valued at over $441.69 million. The company bought an additional 52669.0 shares recently to bring their total holdings to about 4.40% of the shares outstanding. Vanguard Total Stock Market ETF bought 2072.0 shares to see its total holdings expand to 1.66 million shares valued at over $297.99 million and representing 2.97% of the shares outstanding. iShares Core S&P Mid Cap ETF bought 1425.0 shares to bring its total holdings to over 1.58 million shares at a value of $283.65 million. iShares Core S&P Mid Cap ETF now owns shares totaling to 2.83% of the shares outstanding.
Shares of Repligen Corp. (NASDAQ: RGEN) opened at $179.96, up $1.35 from a prior closing price of $178.61. However, the script later moved the day high at 180.54, down -3.02%. The company’s stock has a 5-day price change of 0.92% and 11.95% over the past three months. RGEN shares are trading -3.67% year to date (YTD), with the 12-month market performance down to -2.30% lower. It has a 12-month low price of $110.45 and touched a high of $200.98 over the same period. RGEN has an average intraday trading volume of 706.97K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -3.06%, 5.99%, and 7.84% respectively.
Institutional ownership of Repligen Corp. (NASDAQ: RGEN) shares accounts for 102.84% of the company’s 55.56M shares outstanding. Mutual fund holders own 38.28%, while other institutional holders and individual stakeholders account for 65.44% and 26.09% respectively.
It has a market capitalization of $9.67B and a beta (3y monthly) value of 1.04. The stock’s trailing 12-month PE ratio is 85.30, while the earnings-per-share (ttm) stands at $2.03. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.45% over the week and 3.77% over the month.
Analysts forecast that Repligen Corp. (RGEN) will achieve an EPS of $0.33 for the current quarter, $0.36 for the next quarter and $1.77 for 2024. The lowest estimate earnings-per-share for the quarter is $0.3 while analysts give the company a high EPS estimate of $0.35. Comparatively, EPS for the current quarter was $0.68 a year ago. Earnings per share for the fiscal year are expected to decrease by -47.28%, and 2.50% over the next financial year. EPS should shrink at an annualized rate of -6.23% over the next five years, compared to 35.07% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 13 brokerage firm advisors rate Repligen Corp. (RGEN) as a “Strong Buy” at a consensus score of 1.46. Specifically, 10 Wall Street analysts polled rate the stock as a buy, while 3 of the 13 advise that investors “hold,” and 0 rated it as a “Sell.”
